A PBS listing that allows dual therapy to be prescribed for patients with pulmonary arterial hypertensions (PAH) has been “a long time coming”, says respiratory physician Associate Professor Edmund Lau. From 1 October, patients with WHO Functional Class III and IV PAH can receive subsidised therapy with both an endothelin receptor antagonist (ERA) and phosphodiesterase-5 ...
PBS change opens door to dual therapy for more patients with PAH
By Megan Howe
14 Oct 2020